Evotec SE ADR EVO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Evotec Announces Chief Scientific Officer Transition
-
Just - Evotec Biologics Advances U.S. Department of War Antibodies Against Orthopoxvirus into Phase 1 Clinical Studies
-
Evotec and Plectonic Enter Research Collaboration to Explore New Generation of T-Cell-Engaging Approaches for Solid Tumors
-
Evotec and Odyssey Therapeutics Enter AI-Enabled R&D Collaboration in Autoimmune and Inflammatory Diseases
-
Ad hoc: Evotec Announces Preliminary Second Quarter and First Half 2026 Results and Updates Full-Year 2026 Outlook
Trading Information
- Previous Close Price
- $1.65
- Day Range
- $1.59–1.63
- 52-Week Range
- $1.50–4.27
- Bid/Ask
- $1.53 / $1.70
- Shares Outstanding
- 355.39M
- Market Cap
- $568.62M
- Volume/Avg
- 52,034 / 94,353
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 0.70
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- 0.30%
Company Profile
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Value
- Total Number of Employees
- 4,553
- Website
- https://www.evotec.com
Valuation
|
Metric
|
EVO
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.77 |
Price/Sales | 0.70 |
Price/Cash Flow | — |
Price/Earnings
EVO
Financial Strength
|
Metric
|
EVO
|
|---|---|
Quick Ratio | 2.08 |
Current Ratio | 2.33 |
Interest Coverage | −15.19 |
Quick Ratio
EVO
Profitability
|
Metric
|
EVO
|
|---|---|
Return on Assets (Normalized) | −6.59% |
Return on Equity (Normalized) | −14.65% |
Return on Invested Capital (Normalized) | −8.90% |
Return on Assets
EVO
Drug Manufacturers - Specialty & Generic Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Merck KGaA ADR
MKKGY
| LOCK|BN&#bB& | LOCK|sm>D? | $67B | |||
| Teva Pharmaceutical Industries Ltd
TEVA
| LOCK|?bkR^N? | LOCK|&&$c | $46B | |||
| Haleon PLC ADR
HLN
| LOCK|jz%??M% | LOCK|^#> | $38B | |||
| Zoetis Inc Class A
ZTS
| LOCK|jsp#$@MQ | LOCK|$V | $29B | |||
| Viatris Inc
VTRS
| LOCK|K@wwRTd | LOCK|w^ | $20B | |||
| Elanco Animal Health Inc
ELAN
| LOCK|fn | LOCK|<K | $11B | |||
| Dr Reddy's Laboratories Ltd ADR
RDY
| LOCK|#<HS$^ | LOCK|<< | $10B | |||
| Hims & Hers Health Inc Ordinary Shares - Class A
HIMS
| LOCK|nF>sd# | LOCK|pd^ | $7B | |||
| Prestige Consumer Healthcare Inc
PBH
| LOCK|?T%nt< | LOCK|N%$h | $2B | |||
| Perrigo Co PLC
PRGO
| LOCK|Vk<pZ$ | LOCK|nRZ | $2B |
United States